WASHINGTON — Ned Sharpless has been in cancer research for decades, most recently as the director of the University of North Carolina’s Lineberger Cancer Center. But when he took the helm of the National Cancer Institute in October, he realized it would take time to get to know the $5.5 billion federal agency. So he embarked on a listening tour that ended up lasting six months, talking to investigators, patients, research advocates, and agency administrators.

Seven months into his tenure at NCI, Sharpless sat down with STAT on Wednesday to talk about his new role, using artificial intelligence in cancer care, and how the NIH’s “All of Us” precision medicine project could play into the NCI’s big data aspirations.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy